9p 0.0 0.0%
Last Trade - 21/02/20
| Market Cap | ÂŁ3.14m |
| Enterprise Value | ÂŁ8.93m |
| Revenue | ÂŁ1.50m |
| Position in Universe | 1711th / 1838 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | TTM | 2020E | 2021E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|---|
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2020
|
31st Dec 2021
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Genedrive Plc is a United Kingdom-based holding company engaged in molecular diagnostics business. The Company provides a molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. Its geographical segments include the United Kingdom, Europe, the United States of America and Asia. Genedrive is a small polymerase chain reaction (PCR) platform, which enables nucleic acid amplification and detection from various sample types, including plasma, sputum and buccal swabs. Genedrive system includes Genedrive hepatitis C virus (HCV) ID Kit for detection of Hepatitis C, and Genedrive IL28B ID Kit for the detection of Interleukin 28B genotyping status.
| Last Annual | June 30th, 2019 |
| Last Interim | December 31st, 2019 |
| Incorporated | February 15, 2007 |
| Public Since | April 4, 2007 |
| No. of Shareholders: | n/a |
| No. of Employees: | 44 |
| Sector | Healthcare |
| Industry | Healthcare Providers & Services |
| Index | FTSE Aim All Share , |
| Exchange | London Stock Exchange (AIM) |
| Shares in Issue | 34,870,071 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 48 Grafton Street, MANCHESTER, M13 9XX, United Kingdom |
| Web | http://www.genedriveplc.com/ |
| Phone | +44 161 9890245 |
| Contact | () |
| Auditors | PricewaterhouseCoopers LLP |
